

Company registration number: 05336536

AMENDED FINANCIAL ACCOUNTS

Sentinel Oncology Ltd

Unaudited filleted financial statements

31 March 2021

WEDNESDAY



ABW8E7E

A13

08/02/2023

#86

COMPANIES HOUSE

Sentinel Oncology Ltd

Contents

	Page
Directors and other information	1
Accountants report	2
Statement of financial position	3 - 4
Notes to the financial statements	5 - 9

Sentinel Oncology Ltd

Directors and other information

Directors	Stuart Travers Robert Boyle Gavin Simpson Daniel Cowell John Dixon Ashok Venkitaramen
Secretary	Stuart Travers
Company number	05336536
Registered office	181 Science Park Milton Road Cambridge Cambridgeshire CB4 0GJ
Business address	181 Science Park Milton Road Cambridge Cambridgeshire CB4 0GJ
Accountants	i-Accounting The Enterprise Centre University of East Anglia Norwich Norfolk NR4 7TJ

Sentinel Oncology Ltd

**Report to the board of directors on the preparation of the
unaudited statutory financial statements of Sentinel Oncology Ltd
Year ended 31 March 2021**

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Sentinel Oncology Ltd for the year ended 31 March 2021 which comprise the statement of financial position and related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at <http://www.accaglobal.com/en/member/professional-standards/rules-standards/acca-rulebook.html>.

This report is made solely to the board of directors of Sentinel Oncology Ltd, as a body, in accordance with the terms of our engagement letter dated 28 June 2018. Our work has been undertaken solely to prepare for your approval the financial statements of Sentinel Oncology Ltd and state those matters that we have agreed to state to the board of directors of Sentinel Oncology Ltd as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/content/dam/ACCA_Global/Technical/fact/technical-factsheet-163.pdf. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Sentinel Oncology Ltd and its board of directors as a body for our work or for this report.

It is your duty to ensure that Sentinel Oncology Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Sentinel Oncology Ltd. You consider that Sentinel Oncology Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Sentinel Oncology Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

1- Accounting Solutions

**i-Accounting
Chartered Certified Accountant
The Enterprise Centre
University of East Anglia
Norwich
Norfolk
NR4 7TJ**

20 December 2022

Sentinel Oncology Ltd

**Statement of financial position
31 March 2021**

	Note	£	2021 £	£	2020 £
Fixed assets					
Intangible assets	5	-		260,969	
Tangible assets	6	4,541		5,461	
Investments	7	5		5	
			4,546		266,435
Current assets					
Debtors	8	70,726		137,364	
Cash at bank and in hand		2,706,673		628,658	
		2,777,399		766,022	
Creditors: amounts falling due within one year	9	(1,478,600)		(160,322)	
Net current assets			1,298,799		605,700
Total assets less current liabilities			1,303,345		872,135
Net assets			1,303,345		872,135
Capital and reserves					
Called up share capital			8		8
Share premium account			3,005,061		3,005,061
Profit and loss account			(1,701,724)		(2,132,934)
Shareholders funds			1,303,345		872,135

For the year ending 31 March 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

The notes on pages 5 to 9 form part of these financial statements.

Sentinel Oncology Ltd

Statement of financial position (continued)
31 March 2021

These financial statements were approved by the board of directors and authorised for issue on 19 December 2022, and are signed on behalf of the board by:



Stuart Travers
Director



Robert Boyle
Director

Company registration number: 05336536

The notes on pages 5 to 9 form part of these financial statements.

Sentinel Oncology Ltd

Notes to the financial statements Year ended 31 March 2021

1. General information

The company is a private company limited by shares, registered in England. The address of the registered office is 181 Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0GJ.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. The Triennial review 2017 amendments to the standard have been early adopted.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for services rendered, net of discounts and Value Added Tax.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Sentinel Oncology Ltd

Notes to the financial statements (continued) **Year ended 31 March 2021**

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Fittings fixtures and equipment	- 33%	reducing balance
---------------------------------	-------	------------------

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Fixed asset investments

Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Government grants

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Under the performance model, where the grant does not impose specified future performance-related conditions on the recipient, it is recognised in income when the grant proceeds are received or receivable. Where the grant does impose specified future performance-related conditions on the recipient, it is recognised in income only when the performance-related conditions have been met. Where grants received are prior to satisfying the revenue recognition criteria, they are recognised as a liability.

Sentinel Oncology Ltd

Notes to the financial statements (continued) Year ended 31 March 2021

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are recognised at the transaction price, trade creditors, trade debtors, uk bank accounts. Overseas bank accounts are recognised in sterling using HMRC published exchange rate as at 31 March 2021.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 5 (2020: 5).

5. Intangible assets

	Other intangible assets £	Total £
Cost		
At 1 April 2020	260,969	260,969
Additions	118,699	118,699
Released to profit and loss account	(379,668)	(379,668)
At 31 March 2021	<u>-</u>	<u>-</u>
Amortisation		
At 1 April 2020 and 31 March 2021	<u>-</u>	<u>-</u>
Carrying amount		
At 31 March 2021	<u>-</u>	<u>-</u>
At 31 March 2020	<u>260,969</u>	<u>260,969</u>

Accounting policy has been amended to release all patent costs to the profit and loss account with effect from 1 April 2020.

Sentinel Oncology Ltd

Notes to the financial statements (continued)
Year ended 31 March 2021

6. Tangible assets

	Fixtures, fittings and equipment £	Total £
Cost		
At 1 April 2020	31,613	31,613
Additions	1,316	1,316
At 31 March 2021	<u>32,929</u>	<u>32,929</u>
Depreciation		
At 1 April 2020	26,152	26,152
Charge for the year	2,236	2,236
At 31 March 2021	<u>28,388</u>	<u>28,388</u>
Carrying amount		
At 31 March 2021	<u>4,541</u>	<u>4,541</u>
At 31 March 2020	<u>5,461</u>	<u>5,461</u>

7. Investments

	Investment in a private limited company £	Total £
Cost		
At 1 April 2020 and 31 March 2021	<u>5</u>	<u>5</u>
Impairment		
At 1 April 2020 and 31 March 2021	<u>-</u>	<u>-</u>
Carrying amount		
At 31 March 2021	<u>5</u>	<u>5</u>
At 31 March 2020	<u>5</u>	<u>5</u>

8. Debtors

	2021 £	2020 £
Trade debtors	-	15,116
Other debtors	70,726	122,248
	<u>70,726</u>	<u>137,364</u>

Sentinel Oncology Ltd

Notes to the financial statements (continued)
Year ended 31 March 2021

9. Creditors: amounts falling due within one year

	2021	2020
	£	£
Trade creditors	68,092	99,241
Social security and other taxes	361,008	9,402
Other creditors inc income deferral of £998k	1,049,500	51,679
	<u>1,478,600</u>	<u>160,322</u>